mTor Targeting by Different Flavonoids for Cancer Prevention

(E-pub Ahead of Print)

Author(s): Badar ul Islam, Mohd Shahnawaz Khan, Fohad Mabood Husain, Md Tabish Rehman, Torki A. Alzughaibi, Adel M. Abuzenadah, Maryam Urooj, Mohammad Amjad Kamal, Shams Tabrez*

Journal Name: Current Medicinal Chemistry

Become EABM
Become Reviewer
Call for Editor


Over the past several decades, plant-derived products (phytochemicals) have been suggested to possess immense therapeutic potential. Among these phytochemicals, different flavonoids have been reported for their potent anticancer activity. To exhibit their anticancer potential, these flavonoids modulate different signaling pathways. Among these pathways, the mammalian target of rapamycin (mTOR) and associated phosphatidyl-inositiol 3-kinase (PI3K)/protein kinase B (Akt) signaling cascade has been suggested as a pivotal modulator of cell survival, proliferation, and death/apoptosis. Hence, targeting this cascade could be an ideal strategy to alleviate apoptosis and inhibit proliferation in different forms of cancer. The targeting of PI3K/Akt/mTOR by flavonoids have been well documented in the scientific literature. In the current communication, we have covered the anticancer potential of various flavonoids especially flavones, flavanols, and isoflavones that include apigenin, luteolin, biacalein, tangeretin, epigallocatechin-3-gallate, genistein, and diadzein especially dealing with mTOR targeting.

Keywords: Apigenin, biacalein, cancer prevention, diadzein, epigallocatechin-3-gallate, flavonoids, genistein, luteolin, tangeretin, mTOR

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Ahead of Print)
DOI: 10.2174/0929867327666201109122025
Price: $95

Article Metrics

PDF: 228